NClip

Angiotensin Receptor/Neprilysin Inhibitors

3 min read

Angiotensin Receptor/Neprilysin Inhibitors

Key Points

  • ARNI therapy combines an ARB with neprilysin inhibition to reduce preload/afterload and heart-failure workload.
  • Current class prototype is sacubitril/valsartan.
  • ARNIs are guideline-directed first-line class options in many HFrEF pathways.
  • Major safety risks are hypotension, hyperkalemia, renal impairment, and angioedema.
  • ARNIs are contraindicated in pregnancy and in clients with prior ACE inhibitor/ARB-associated angioedema.
  • Do not combine ACE inhibitors, ARBs, and ARNIs concurrently.

Pathophysiology

In HFrEF, ventricular stress and dilation increase myocardial release of natriuretic peptides such as BNP. These peptides support compensatory vasodilation and natriuresis, which can reduce afterload and preload.

Neprilysin breaks down BNP. ARNI therapy inhibits neprilysin (sacubitril component), prolonging natriuretic-peptide effect, while valsartan blocks angiotensin II receptor activity. The combined effect supports vasodilation, reduced sodium/water retention, and lower cardiac workload.

Nursing Assessment

NCLEX Focus

Priorities are hypotension/hyperkalemia surveillance, renal trend monitoring, and strict reconciliation to prevent duplicate RAAS-class therapy.

  • Assess baseline blood pressure, renal function, and potassium before initiation and during titration.
  • Review full medication list, including OTC/herbal products, for interacting agents.
  • Screen for contraindications: pregnancy, prior ACE inhibitor/ARB angioedema history, or severe intolerance to RAAS therapy.
  • Assess for hepatic impairment, renal impairment, hypovolemia, and baseline hypotension risk before dose escalation.

Nursing Interventions

  • Monitor blood pressure trend and orthostatic symptoms during initiation and dose changes.
  • Monitor potassium and kidney-function trends; escalate rising creatinine, oliguria, or dyskalemia findings promptly.
  • Reconcile high-risk interactions: ACE inhibitors, potassium-sparing diuretics, NSAIDs, and lithium.
  • Reinforce that only one major RAAS-class pathway should be active at a time (ACE inhibitor vs ARB vs ARNI).
  • Teach avoidance of high-potassium foods/salt substitutes when hyperkalemia risk is elevated.
  • Counsel clients to report dizziness, syncope, facial/tongue swelling, decreased urine output, or persistent GI/muscle symptoms.

Angioedema and Pregnancy Risk

ARNIs can cause life-threatening angioedema and are contraindicated in pregnancy due to fetal toxicity risk.

Pharmacology

Drug/ClassTypical DoseKey RN Considerations
Sacubitril/valsartan (ARNI)Initial 49 mg/51 mg PO twice daily; max 97 mg/103 mg PO twice dailyMonitor BP, potassium, and renal function; avoid concurrent ACE inhibitor/ARB therapy; assess for angioedema and hypotension

Clinical Judgment Application

Clinical Scenario

A client with symptomatic HFrEF is transitioned from prior RAAS therapy to sacubitril/valsartan and reports dizziness after the first week.

  • Recognize Cues: Dizziness after ARNI initiation with potential BP-lowering effect.
  • Analyze Cues: Symptomatic hypotension or volume depletion is likely.
  • Prioritize Hypotheses: Hemodynamic intolerance and/or medication interaction need immediate review.
  • Generate Solutions: Reassess BP/orthostatics, review interacting drugs, and trend potassium/renal labs.
  • Take Action: Notify provider for dose/timing reassessment and reinforce safety/fall precautions.
  • Evaluate Outcomes: Symptoms stabilize with safe BP, kidney, and potassium trends.

Self-Check

  1. Why is ARNI therapy incompatible with concurrent ACE inhibitor/ARB duplication?
  2. Which laboratory and hemodynamic trends are most important after ARNI initiation?
  3. What symptoms require urgent escalation in a client taking sacubitril/valsartan?

Graph View

Backlinks